An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gamida Cell to Present at Society for Immunotherapy of Cancer';s (SITC) 36th Annual Meeting
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Gamida Cell (NASDAQ: GMDA) announced that data on its NAM-enabled NK cell platform will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) from November 10-14, 2021, in Washington, DC, and virtually. Key presentations include findings on GDA-201's cytotoxicity and tumor-killing capabilities of nicotinamide-enhanced NK cells. GDA-201 is an investigational NK cell immunotherapy targeting hematologic and solid tumors, showing promising initial clinical trial results.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that data evaluating the company’s NAM-enabled NK cell platform will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) taking place in Washington, DC, and virtually November 10-14, 2021.
Details about the SITC poster presentations are as follows:
Title: Cytotoxicity of nicotinamide enhanced natural killer cells GDA-201 is based on metabolic modulation as demonstrated by AI assisted analysis of NK cell transcriptome and metabolome
Abstract number: 217
Time: Friday, November 12, 2021, 7:00 a.m. – 8:30 p.m. EST Location: Hall E
Title: Nicotinamide rejuvenates ex-vivo expanded NK cells and enhances their tumor killing capacity
Abstract Number: 162
Time: Saturday, November 13, 2021, 7:00 a.m. – 8:30 p.m. EST Location: Hall E
About GDA-201
Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results, as reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition1. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. For more information about GDA-201, please visit https://www.gamida-cell.com.
GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.
About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates, anticipated regulatory filings (including the submission of the BLA for omidubicel to the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations regarding its projected cash to be used for operating activities and cash runway. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.
What is Gamida Cell's GDA-201 and its significance?
GDA-201 is an NK cell immunotherapy developed by Gamida Cell (NASDAQ: GMDA) aimed at treating hematologic and solid tumors by enhancing the cytotoxicity of natural killer cells.
When will Gamida Cell present data on GDA-201?
Gamida Cell will present data on GDA-201 at the SITC 2021 Annual Meeting, scheduled for November 10-14, 2021.
What are the key presentation details for Gamida Cell at SITC 2021?
Key presentations include: 1) 'Cytotoxicity of nicotinamide enhanced natural killer cells GDA-201' on November 12, 2021, and 2) 'Nicotinamide rejuvenates ex-vivo expanded NK cells' on November 13, 2021.
What outcomes does Gamida Cell expect from GDA-201?
Gamida Cell expects GDA-201 to improve natural killer cell cytotoxicity, retention, and proliferation, enhancing their effectiveness against tumors.
What is the timeline for Gamida Cell's clinical trials?
Gamida Cell's clinical trial timelines and results, including for GDA-201, are subject to uncertainties, as highlighted in their forward-looking statements.
